EA201891882A1 - НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ - Google Patents

НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ

Info

Publication number
EA201891882A1
EA201891882A1 EA201891882A EA201891882A EA201891882A1 EA 201891882 A1 EA201891882 A1 EA 201891882A1 EA 201891882 A EA201891882 A EA 201891882A EA 201891882 A EA201891882 A EA 201891882A EA 201891882 A1 EA201891882 A1 EA 201891882A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sirpa
options
new antibodies
therapeutic application
interaction
Prior art date
Application number
EA201891882A
Other languages
English (en)
Inventor
Николя Пуарье
Каролина Мари
Бернард Ванхове
Ванесса Готье
Виржини Тепенье
Сабрина Пенгам
Original Assignee
Осе Иммьюнотерапьютикс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Осе Иммьюнотерапьютикс filed Critical Осе Иммьюнотерапьютикс
Publication of EA201891882A1 publication Critical patent/EA201891882A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Abstract

Настоящее изобретение относится к новым антителам к SIRPa, способным оказывать специфическое антагонистическое действие на взаимодействие SIRPa с CD47, не оказывая отрицательного влияния на взаимодействие SIRPg с CD47, а также к вариантам их применения.
EA201891882A 2017-02-17 2017-04-14 НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ EA201891882A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305182 2017-02-17
PCT/EP2017/059071 WO2017178653A2 (en) 2016-04-14 2017-04-14 NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

Publications (1)

Publication Number Publication Date
EA201891882A1 true EA201891882A1 (ru) 2019-07-31

Family

ID=58185461

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891882A EA201891882A1 (ru) 2017-02-17 2017-04-14 НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ

Country Status (10)

Country Link
EP (1) EP3443010A2 (ru)
CN (1) CN109071664B (ru)
AU (1) AU2017248626A1 (ru)
BR (1) BR112018070823A2 (ru)
CA (1) CA3020373A1 (ru)
CO (1) CO2018010855A2 (ru)
EA (1) EA201891882A1 (ru)
PE (1) PE20181921A1 (ru)
SG (1) SG11201808465UA (ru)
WO (1) WO2017178653A2 (ru)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180778A1 (es) 2015-08-07 2018-05-07 Alexo Therapeutics Inc Construcciones con un dominio sirp-alfa o sus variantes
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CA3044684A1 (en) 2016-12-09 2018-06-14 Alector Llc Anti-sirp-alpha antibodies and methods of use thereof
KR20190117670A (ko) * 2017-02-17 2019-10-16 오제 이뮈노테라프틱스 항-SIRPg 항체의 새로운 용도
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
WO2018210793A2 (en) * 2017-05-16 2018-11-22 Synthon Biopharmaceuticals B.V. ANTI-SIRPα ANTIBODIES
BR112020001679A2 (pt) 2017-08-02 2020-07-21 Phanes Therapeutics, Inc. anticorpos anti-cd47 e usos dos mesmos
JP7395471B2 (ja) 2017-10-13 2023-12-11 オーセ イミュノセラピューティクス 改変抗ＳＩＲＰａ抗体及びその使用
EP3700938A1 (en) * 2017-10-26 2020-09-02 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. Novel recombinant fusion proteins, preparation and use thereof
CA3091468A1 (en) 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
CA3093838A1 (en) * 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
CA3094098A1 (en) * 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
CA3098710A1 (en) 2018-05-25 2019-11-28 Alector Llc Anti-sirpa antibodies and methods of use thereof
WO2020013170A1 (ja) * 2018-07-10 2020-01-16 国立大学法人神戸大学 抗ＳＩＲＰα抗体
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
KR20210086619A (ko) * 2018-09-27 2021-07-08 셀진 코포레이션 SIRPα 결합 단백질 및 이의 사용 방법
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
GB2593632B (en) 2018-10-29 2023-05-24 Umc Utrecht Holding Bv IGA mediated killing of aberrant cells by CD47-Sirpalpha checkpoint inhibition of neutrophils
JP2022507295A (ja) * 2018-11-14 2022-01-18 アーチ オンコロジー，インコーポレイテッド 治療用ＳＩＲＰα抗体
AU2019378101A1 (en) * 2018-11-15 2021-05-27 Byondis B.V. Humanized anti-SIRPα antibodies
US20220143210A1 (en) * 2019-02-27 2022-05-12 Fred Hutchinson Cancer Research Center Hydrogel compositions and methods for treatement of malignancies
US20220235144A1 (en) * 2019-03-04 2022-07-28 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
WO2020243338A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
JP2022535286A (ja) 2019-06-07 2022-08-05 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
EP3990476A1 (en) 2019-06-25 2022-05-04 Gilead Sciences, Inc. Flt3l-fc fusion proteins and methods of use
EP3756688A1 (en) 2019-06-25 2020-12-30 Université de Nantes Inhibitor of surface protein (sp-d) / sirpa / shp2 pathway for use in the prevention and/or treatment of secondary infection
AU2020286285A1 (en) * 2019-08-20 2021-03-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-SIRPa antibodies
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
JP2023503943A (ja) 2019-11-27 2023-02-01 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための組み合わせ療法
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
CN111116713B (zh) * 2020-01-07 2023-06-23 郑州大学 Sirpa蛋白亲和环肽及其应用
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
CA3169523A1 (en) 2020-02-28 2021-09-02 Jaume Pons Transglutaminase-mediated conjugation
BR112022021447A2 (pt) 2020-05-19 2022-12-13 Boehringer Ingelheim Int Moléculas de ligação para o tratamento de câncer
KR20230018475A (ko) 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
AU2021378152A1 (en) 2020-11-11 2023-06-22 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
JP2024501134A (ja) 2020-11-30 2024-01-11 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗ＳＩＲＰα抗体またはその抗原結合断片および適用
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
EP4337190A1 (en) 2021-05-13 2024-03-20 ALX Oncology Inc. Combination therapies for treating cancer
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
CN117355539A (zh) * 2021-05-28 2024-01-05 百奥泰生物制药股份有限公司 抗SIRPα抗体及其应用
IL308741A (en) 2021-06-04 2024-01-01 Boehringer Ingelheim Int Anti-SIRP-alpha antibodies
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309405A (en) 2021-06-29 2024-02-01 Seagen Inc Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
CN116472351A (zh) 2021-08-17 2023-07-21 杭州九源基因工程有限公司 靶向SIRPα的单克隆抗体及其用途
TW202330504A (zh) 2021-10-28 2023-08-01 美商基利科學股份有限公司 嗒𠯤—３（２ｈ）—酮衍生物
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
WO2023094698A1 (en) 2021-11-29 2023-06-01 Ose Immunotherapeutics Specific antagonist anti-sirpg antibodies
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100215640A1 (en) * 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) * 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CN101780283A (zh) * 2010-03-16 2010-07-21 中国人民解放军第二军医大学 信号调节蛋白α在制备预防和治疗肿瘤的DC疫苗中的应用
CN101880324B (zh) * 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies

Also Published As

Publication number Publication date
CA3020373A1 (en) 2017-10-19
WO2017178653A3 (en) 2018-07-05
PE20181921A1 (es) 2018-12-11
EP3443010A2 (en) 2019-02-20
CN109071664B (zh) 2023-02-21
CO2018010855A2 (es) 2018-11-13
BR112018070823A2 (pt) 2019-02-05
AU2017248626A1 (en) 2018-10-11
SG11201808465UA (en) 2018-10-30
CN109071664A (zh) 2018-12-21
WO2017178653A2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
EA201891882A1 (ru) НОВЫЕ АНТИТЕЛА К SIRPa И ВАРИАНТЫ ИХ ТЕРАПЕВТИЧЕСКОГО ПРИМЕНЕНИЯ
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
EA201890441A1 (ru) Моноклональные антитела против bcma
CY1123259T1 (el) Αντισωματα anti-pvrig και μεθοδοι χρησης
CO2019003943A2 (es) Proteínas de fusión fc heterodiméricas il15/il15rα
SA517381604B1 (ar) أجسام مضادة ديمرية غير متجانسة جديدة
EA201691991A1 (ru) Мультиспецифические антитела
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
EA201790548A1 (ru) Варианты комбинированной терапии анти-cd38 антителами
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201690314A1 (ru) Анти-garp-белок и его применения
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
PH12018550160A1 (en) NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
CL2020002540A1 (es) Anticuerpos anti-hla-g y utilización de los mismos
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA201891299A1 (ru) Терапевтические антитела к cd9
EA202091521A1 (ru) ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2